SCHEMBL25211173

SCHEMBL25211173

COC(=O)c1cnc2c(ccn2CC(=O)OC(C)(C)C)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PSMD14 O00487 1/20 0.39
▸ HDAC6 Q9UBN7 2/20 0.39
▸ KDM4E B2RXH2 3/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ HPGD P15428 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ APOBEC3A P31941 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ APOBEC3G Q9HC16 1/20 0.38
▸ JAK2 O60674 2/20 0.38
▸ JAK1 P23458 2/20 0.38
▸ JAK3 P52333 2/20 0.38
▸ FPR2 P25090 3/20 0.37
▸ MAPK1 P28482 1/20 0.36
▸ LMNA P02545 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28928193 0.88 HDAC6 (0.40) HDAC6KDM4EALDH1A1JAK2JAK1
SCHEMBL23885053 0.84 PSMD14 (0.43) PSMD14KDM4EALDH1A1HPGDPOLB
SCHEMBL31403654 0.81 PSMD14 (0.45) PSMD14KDM4EALDH1A1HPGDPOLB
SCHEMBL3592491 0.75 MTNR1A (0.52) HDAC6KDM4EALDH1A1FPR2
SCHEMBL23885083 0.75 FPR2 (0.43) HDAC6KDM4EALDH1A1JAK2JAK1
SCHEMBL13199654 0.74 PSMD14 (0.48) PSMD14KDM4EALDH1A1SMN1; SMN2MAPK1
SCHEMBL31637252 0.73 HDAC6 (0.43) HDAC6KDM4EALDH1A1JAK2JAK1
SCHEMBL15936536 0.73 HDAC3 (0.60) PSMD14KDM4EALDH1A1SMN1; SMN2MAPK1
SCHEMBL19208142 0.73 JAK2 (0.39) PSMD14KDM4EALDH1A1JAK2JAK1
SCHEMBL26433120 0.73 MET (0.39) PSMD14HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-05-25 — — US disclosed
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-05-25 — — US disclosed
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-05-25 — — US disclosed
CN-115427044-A Pyrrolopyrimidines as complement inhibitors 拜奥克里斯特制药公司 2022-12-02 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS C5, C9, C1QBP PSMD14 3137/4885HDAC6 2412/4885KDM4E 3581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback